Literature DB >> 31619570

CaM kinase II regulates cardiac hemoglobin expression through histone phosphorylation upon sympathetic activation.

Ali Reza Saadatmand1,2,3, Viviana Sramek1,2, Silvio Weber3, Daniel Finke1,2,4, Matthias Dewenter1,2, Carsten Sticht5, Norbert Gretz5, Till Wüstemann1,2, Marco Hagenmueller1,2, Stephan R Kuenzel3, Stefanie Meyer-Roxlau3, Martin Kramer3, Samuel Sossalla6,7,8, Lorenz H Lehmann1,2,4, Susanne Kämmerer3, Johannes Backs9,2, Ali El-Armouche10.   

Abstract

Sympathetic activation of β-adrenoreceptors (β-AR) represents a hallmark in the development of heart failure (HF). However, little is known about the underlying mechanisms of gene regulation. In human ventricular myocardium from patients with end-stage HF, we found high levels of phosphorylated histone 3 at serine-28 (H3S28p). H3S28p was increased by inhibition of the catecholamine-sensitive protein phosphatase 1 and decreased by β-blocker pretreatment. By a series of in vitro and in vivo experiments, we show that the β-AR downstream protein kinase CaM kinase II (CaMKII) directly binds and phosphorylates H3S28. Whereas, in CaMKII-deficient myocytes, acute catecholaminergic stimulation resulted in some degree of H3S28p, sustained catecholaminergic stimulation almost entirely failed to induce H3S28p. Genome-wide analysis of CaMKII-mediated H3S28p in response to chronic β-AR stress by chromatin immunoprecipitation followed by massive genomic sequencing led to the identification of CaMKII-dependent H3S28p target genes. Forty percent of differentially H3S28p-enriched genomic regions were associated with differential, mostly increased expression of the nearest genes, pointing to CaMKII-dependent H3S28p as an activating histone mark. Remarkably, the adult hemoglobin genes showed an H3S28p enrichment close to their transcriptional start or end sites, which was associated with increased messenger RNA and protein expression. In summary, we demonstrate that chronic β-AR activation leads to CaMKII-mediated H3S28p in cardiomyocytes. Thus, H3S28p-dependent changes may play an unexpected role for cardiac hemoglobin regulation in the context of sympathetic activation. These data also imply that CaMKII may be a yet unrecognized stress-responsive regulator of hematopoesis.

Entities:  

Keywords:  gene expression; heart; histone phosphorylation

Year:  2019        PMID: 31619570      PMCID: PMC6825262          DOI: 10.1073/pnas.1816521116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

Review 1.  Chromatin modifications and their function.

Authors:  Tony Kouzarides
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

2.  Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing.

Authors:  Priscilla Nga Ieng Lau; Peter Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 3.  Regulation of nucleosome dynamics by histone modifications.

Authors:  Gabriel E Zentner; Steven Henikoff
Journal:  Nat Struct Mol Biol       Date:  2013-03       Impact factor: 15.369

4.  Cardiac CaM Kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy.

Authors:  Michael M Kreusser; Lorenz H Lehmann; Stanislav Keranov; Marc-Oscar Hoting; Ulrike Oehl; Michael Kohlhaas; Jan-Christian Reil; Kay Neumann; Michael D Schneider; Joseph A Hill; Dobromir Dobrev; Christoph Maack; Lars S Maier; Hermann-Josef Gröne; Hugo A Katus; Eric N Olson; Johannes Backs
Journal:  Circulation       Date:  2014-08-14       Impact factor: 29.690

Review 5.  The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes.

Authors:  Edwin Smith; Ali Shilatifard
Journal:  Mol Cell       Date:  2010-12-10       Impact factor: 17.970

6.  Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice.

Authors:  Pei-Lun Hsu; Lin-Yea Horng; Kang-Yung Peng; Chia-Ling Wu; Hui-Ching Sung; Rong-Tsun Wu
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

7.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

8.  H3S28 phosphorylation is a hallmark of the transcriptional response to cellular stress.

Authors:  Anna Sawicka; Dominik Hartl; Malgorzata Goiser; Oliver Pusch; Roman R Stocsits; Ido M Tamir; Karl Mechtler; Christian Seiser
Journal:  Genome Res       Date:  2014-08-18       Impact factor: 9.043

9.  Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo.

Authors:  Ralf Gilsbach; Martin Schwaderer; Sebastian Preissl; Björn A Grüning; David Kranzhöfer; Pedro Schneider; Thomas G Nührenberg; Sonia Mulero-Navarro; Dieter Weichenhan; Christian Braun; Martina Dreßen; Adam R Jacobs; Harald Lahm; Torsten Doenst; Rolf Backofen; Markus Krane; Bruce D Gelb; Lutz Hein
Journal:  Nat Commun       Date:  2018-01-26       Impact factor: 14.919

Review 10.  Physiological and unappreciated roles of CaMKII in the heart.

Authors:  Jan Beckendorf; Maarten M G van den Hoogenhof; Johannes Backs
Journal:  Basic Res Cardiol       Date:  2018-06-15       Impact factor: 17.165

View more
  1 in total

1.  MSK-Mediated Phosphorylation of Histone H3 Ser28 Couples MAPK Signalling with Early Gene Induction and Cardiac Hypertrophy.

Authors:  Emma L Robinson; Faye M Drawnel; Saher Mehdi; Caroline R Archer; Wei Liu; Hanneke Okkenhaug; Kanar Alkass; Jan Magnus Aronsen; Chandan K Nagaraju; Ivar Sjaastad; Karin R Sipido; Olaf Bergmann; J Simon C Arthur; Xin Wang; H Llewelyn Roderick
Journal:  Cells       Date:  2022-02-09       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.